Clinical Trials Sponsored by Actavis Inc.

Total 35660 results

Aclaris Therapeutics, Inc.

Completed

Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT)

Alopecia Totalis (AT) | Alopecia Universalis (AU)

United States
Aclaris Therapeutics, Inc.

Completed

An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses (SK-FAN)

Seborrheic Keratosis

United States
Aclaris Therapeutics, Inc.

Completed

Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Participants With Rosacea

Rosacea

United States
Aclaris Therapeutics, Inc.

Completed

A Phase2 of A-101 Topical Solution in Subjects With Common Warts

Common Wart

United States
Aclaris Therapeutics, Inc.

Completed

Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic Keratosis

Seborrheic Keratosis (SK)

United States
Aclaris Therapeutics, Inc.

Completed

A Study of A-101 Solution in Subjects With Common Warts.

Common Warts

United States
Aclaris Therapeutics, Inc.

Terminated

Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic Arthritis

Psoriatic Arthritis

United States, Poland
Aclaris Therapeutics, Inc.

Completed

ATI-450 vs Placebo in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)

Hidradenitis Suppurativa

United States
Aclaris Therapeutics, Inc.

Terminated

Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS)

Cryopyrin-Associated Periodic Syndrome

United States
Aclaris Therapeutics, Inc.

Completed

Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA

Rheumatoid Arthritis

United States
Aclaris Therapeutics, Inc.

Completed

A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo

Vitiligo

United States
Aclaris Therapeutics, Inc.

Completed

A Study of A-101 Topical Solution for the Treatment of Common Warts

Common Wart

United States
Aclaris Therapeutics, Inc.

Terminated

ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT)

Alopecia Areata | Alopecia Totalis | Alopecia Universalis

United States
Aclaris Therapeutics, Inc.

Completed

Study of A-101 Topical Solution for the Treatment of Common Warts

Common Wart

United States
Aclaris Therapeutics, Inc.

Completed

A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis

Atopic Dermatitis

United States
Aclaris Therapeutics, Inc.

Completed

A Randomized, Vehicle-Controlled Study of 2 Concentrations of A-101 for the Treatment of Seborrheic Keratosis

Seborrheic Keratosis

United States
Aclaris Therapeutics, Inc.

Completed

Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis

Atopic Dermatitis

United States
Aclaris Therapeutics, Inc.

Completed

Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis

Atopic Dermatitis

United States
Aclaris Therapeutics, Inc.

Completed

A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution

Androgenetic Alopecia

United States
Aclaris Therapeutics, Inc.

Completed

Study of A-101 for the Treatment of Seborrheic Keratosis

Seborrheic Keratosis

United States
Aclaris Therapeutics, Inc.

Completed

ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis

Alopecia

United States
Aclaris Therapeutics, Inc.

Terminated

A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata

Alopecia Areata

United States
Aclaris Therapeutics, Inc.

Completed

A Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa Nigra

Dermatosis Papulosa Nigra

United States
Aclaris Therapeutics, Inc.

Completed

Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia Areata

Alopecia Areata | Alopecia Totalis | Alopecia Universalis

United States
Aclaris Therapeutics, Inc.

Completed

A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts

Common Wart

United States
Aclaris Therapeutics, Inc.

Completed

Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis

Seborrheic Keratosis

United States
Aclaris Therapeutics, Inc.

Completed

An Open-Label Safety Study of A-101 Solution

Seborrheic Keratosis

United States
Aclaris Therapeutics, Inc.

Completed

A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis.

Seborrheic Keratosis

United States
Aclaris Therapeutics, Inc.

Completed

A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic Keratosis (SK)

Seborrheic Keratosis

United States
Beth Israel Deaconess Medical Center
Actavis Inc.

Terminated

Pancreatic Enzyme Supplementation for Celiac Disease

Celiac Disease

United States
Actavis Mid-Atlantic LLC

Completed

Bioequivalence Study Comparing Clindamycin Phosphate (1.2%) and Tretinoin (0.025%) Topical Gel to Ziana and Placebo

MILD TO SEVERE ACNE VULGARIS

India
Actavis Mid-Atlantic LLC

Completed

A Bioequivalence Study With Clinical Endpoints Comparing Generic Imiquimod Cream, 3.75% and Zyclara™ (Imiquimod) Cream, 3.75% in Subjects With Actinic Keratoses

Actinic Keratoses

United States
Actavis Mid-Atlantic LLC

Completed

A Bioequivalence Study With Clinical Endpoints Comparing Adapalene and Benzoyl Peroxide Topical Gel 0.1%/2.5% (Actavis Mid-Atlantic LLC) To Epiduo™ (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% (Galderma Laboratories, L.P.) in the Treatment of Mild to Severe Acne Vulgaris

Acne Vulgaris

United States, Belize, India
Lactalis

Completed

Tolerance and Digestibility of a New Formula in Healthy Infants

Growth | Steatorrhea

France
Lactalis

Completed

Tolerance and Growth Outcomes in Children Diagnosed With Cow's Milk Protein Allergy and Prescribed an Extensively Hydrolyzed Casein Formula (Damira 2000©) in Spain (DELISA)

Cow's Milk Protein Allergy

Spain
Lactalis

Completed

Effect of a Mix of Dairy Lipids and Plant Oils in Infant Formula on Omega-3 Fatty Acid in Red Blood Cells (REBECA)

Infant Development

Italy
Lactalis
BioFortis

Terminated

Evaluation of Gastrointestinal pH and Motility After the Consumption of Milk (ROVER)

Healthy

France
Lactalis
Clinact

Withdrawn

Specific Enteral Nutrition in Malnourished, Dialysis Patients With Chronic Kidney Disease. Efficacy, Safety, Quality of Life (AL-EN-PHED)

Quality of Life | Chronic Kidney Disease | Tolerance | Renal Failure Chronic Requiring Hemodialysis | Appetite and General Nutritional Disorders | Severe Malnutrition | Activity

France
Clavis Pharma

Completed

Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML) (CLAVELA)

Acute Myeloid Leukemia (AML)

United States, Spain, France, Ireland, United Kingdom, Australia, Belgium, Canada, Germany, Italy, Norway, Poland, Romania
Clavis Pharma

Completed

A Study of CP-4126 in Patients With Advanced Pancreatic Cancer

Advanced Adenocarcinoma of Pancreas

Norway, Belgium
Clavis Pharma

Completed

A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies

AML | Hematologic Malignancies

United States, United Kingdom, France, Germany, Italy, Norway
Clavis Pharma

Completed

A Phase I/II Study of CP-4055 in Patients With Platinum Resistant Ovarian Cancer

Ovarian Cancer

Belgium, Italy
Clavis Pharma

Completed

Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma

Malignant Melanoma

United States, Sweden, Norway
Clavis Pharma

Completed

Elacytarabine Mass Balance Study in Healthy Volunteers

Not Applicable as This is a Mass Balance/Pharmacokinetic Study Performed in Healthy Subjects

United Kingdom
Clavis Pharma

Completed

A Phase I Clinical Study of Oral CP-4126 in Patients With Advanced Solid Tumour

Solid Tumors

Netherlands, Belgium
Clavis Pharma

Completed

A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer

Colorectal Cancer | Advanced Colorectal Cancer

United Kingdom
Washington University School of Medicine
Aclaris Therapeutics, Inc.

Withdrawn

ATI-2231 in Advanced Solid Tumor Malignancies

Advanced Solid Tumor | Advanced Solid Tumor Malignancies

United States
Lactalis
Biosearch S.A.

Completed

Tolerance of Infants With Cow's Milk Protein Allergy to Extensively Hydrolyzed Rice Protein or Casein Infant Formulas (JUNGLO)

Growth Failure | Tolerance | Cow Milk Protein Sensitivity

Spain
Cytavis Biopharma GmbH

Completed

CY503 for the Treatment of Malignant Melanoma Stage IV After Failure of Prior Therapy

Melanoma

Germany
Clavis Pharma

Completed

Clinical Study of Previously Untreated Patients With Malignant Melanoma

Neoplasm Metastasis | Malignant Melanoma

United States, Norway, Sweden

3

Subscribe